# Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

> **NCT03485287** · PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** Midomafetamine HCl
- **BEHAVIORAL:** Manualized therapy

## Key facts

- **NCT ID:** NCT03485287
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-13
- **Primary completion:** 2019-06-04
- **Final completion:** 2019-06-04
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485287, "Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03485287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*